Trial
NCT02966730
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Fox Chase Cancer Center; Pharmacyclics LLC.
Condition
Follicular Lymphoma
Intervention
Ibrutinib
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-13